
Pillar 1 of 4
GLP-1 Pathway
Supports appetite regulation and slowed gastric emptying, the foundation of modern incretin therapy, refined for patients who need more than a single pathway.

Triple-Hormone Weight Support
Retatrutide prescribed by licensed physicians and compounded at a U.S. 503A pharmacy, built for patients who've stalled on semaglutide or tirzepatide.
You save $100
Physician-prescribed · Billed monthly
Free
30-Day Money-Back Guarantee
$250
Free Doctor Consult
Valued at $250
Locked
Refills Ship Every 30 Days|Stop or Cancel Anytime
Retatrutide is a triple-hormone agonist (GLP-1, GIP, and glucagon) prescribed by licensed U.S. physicians and compounded at a licensed 503A pharmacy. Built for patients who want physician-guided weight support beyond single- or dual-agonist therapy.
If you've stalled on semaglutide or tirzepatide, retatrutide adds a third pathway associated with energy expenditure. Your Direct Reta physician reviews your history and determines whether a retatrutide plan is appropriate for you.
Every plan includes a physician consult and review, compounded medication to your prescribed dose, discreet temperature-controlled shipping, and ongoing clinical support. No insurance required. Cancel anytime, no contracts.
Supports appetite control, plateau breakthrough for patients stuck on prior GLP therapies, physician-guided titration from 1–8 mg, and legitimate prescription care from a U.S. 503A pharmacy, not research-use-only vials.
Use only as prescribed by your licensed physician. Typical plans follow a weekly titration schedule with clinical check-ins. Complete your free consult first, dosing is individualized after medical review.
Yes. If the plan is not right for you, cancel anytime and we refund every month that has not shipped. No contracts, no cancellation fees, no phone calls required.
Phase 3 Studied.
When triple-hormone science meets physician oversight and 503A compounding, the difference is process, not a grey-market vial.
Avg. weight loss at 80 weeks (12 mg, TRIUMPH-1)
Participants in Phase 3 TRIUMPH-1
Hormone receptors targeted
U.S. pharmacy compounding standard
Licensed physician required · Individual results vary

Pillar 1 of 4
Supports appetite regulation and slowed gastric emptying, the foundation of modern incretin therapy, refined for patients who need more than a single pathway.
From appetite control to plateau support, here's what Direct Reta is built to help with once it's part of your care plan.

Three receptors. One physician-guided prescription. Phase 3 trial data and licensed 503A compounding behind every order.

Retatrutide engages GLP-1 and GIP pathways involved in appetite regulation, the same systems targeted by semaglutide and tirzepatide, with an additional glucagon mechanism studied for energy expenditure.

Many patients level off on single- or dual-agonist therapy. Retatrutide's triple-agonist profile is being studied specifically for effects beyond what those pathways alone achieved.

Your prescribing physician selects and adjusts your dose over time, the same titration approach used with other incretin therapies, across a wider dose range.

Every order starts with a licensed physician evaluation and is compounded by a U.S. 503A pharmacy. No grey-market vials labeled "not for human consumption."


Your Wellness
Direct Reta is built for clinical care, not quick fixes. Here's how things typically progress once you're enrolled.
Start My Journey →Physician evaluation required · Cancel anytime
Satisfaction guarantee on every unshipped month
Semaglutide works through GLP-1. Tirzepatide adds GIP. As the body adapts, weight loss can level off. Retatrutide adds a third mechanism (glucagon receptor activity) studied for patients whose results plateaued on single- or dual-agonist therapy.
Receptor targets
GLP-1 only
Mechanism
Appetite suppression, slowed gastric emptying
Typically prescribed after
First-line GLP-1 therapy
Receptor targets
GLP-1 + GIP
Mechanism
Appetite suppression + improved insulin sensitivity
Typically prescribed after
Semaglutide plateau or insufficient response
Receptor targets
GLP-1 + GIP + Glucagon
Mechanism
Appetite + insulin sensitivity + energy expenditure via glucagon
Typically prescribed after
Tirzepatide plateau, or patients seeking a third mechanism
Retatrutide is investigational; clinical trials are ongoing. Individual results vary. This is not a claim of superiority backed by head-to-head trial data.
Why it matters
Most retatrutide sold online today is labeled RUO, no prescription, no physician, no pharmacy-grade controls. Direct Reta starts with a licensed physician and is compounded by a U.S. 503A pharmacy under federal sterile-compounding standards.
Requires a prescription
Licensed physician reviews your health history
Compounded under USP <797> sterile compounding standards
Potency & sterility tested before it ships
Made in an FDA-registered compounding facility
Legally labeled "not for human consumption"
One care plan with everything included: physician consult, compounded medication, and ongoing support. Cancel anytime.
You save $100
Physician-prescribed · Billed monthly
Free
30-Day Money-Back Guarantee
$250
Free Doctor Consult
Valued at $250
Locked
Refills Ship Every 30 Days|Stop or Cancel Anytime
Rated 4.9 / 5 | Trusted by patients nationwide
I was stuck for months on the highest tirzepatide dose. After switching through Direct Reta, my physician titrated carefully and the scale started moving again. The prescription process felt legitimate, not like ordering peptides online.
I'd looked at research-use-only sites and didn't trust them. Direct Reta connected me with a licensed physician and the medication came from a compounding pharmacy. Night and day difference in peace of mind.
Starting low and stepping up with clinical support made the whole thing feel manageable. Appetite quieted, energy felt steadier, and I always knew who to message with questions.